Pablo Legorreta, Royalty Pharma CEO (Patrick T. Fallon/Bloomberg via Getty Images)
June 8, 2020 04:17 PM EDT
Financing

Cap­i­tal­iz­ing Pablo II: The up­dat­ed IPO for Roy­al­ty Phar­ma in­cludes a $16.6B mar­ket cap and a chart-top­ping $2.2B raise. Can they beat it?

John Carroll

Editor & Founder

Pablo Legor­re­ta has sent in his up­dat­ed S-1 for Roy­al­ty Phar­ma, which pre­dictably sketch­es out a much big­ger pic­ture than the place­hold­er sent in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times